 |
97 Diseases |  |
247 Trials |
|
247 Trials |  |
14602 News |  |
| «12...159160161162163164165166167168169170171» |
- | rivaroxaban / Generic mfg.
New P1 trial: A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis (clinicaltrials.gov) - Nov 13, 2014
P1, N=16, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- |||||| Xarelto (rivaroxaban) / J&J
Enrollment open, Trial initiation date: RASET: Rivaroxaban Anticoagulation for Superficial Vein Thrombosis (clinicaltrials.gov) - Nov 13, 2014
P3, N=600, Recruiting, Sponsor: McMaster University
Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Nov 2014
- ||| rivaroxaban / Generic mfg.
Enrollment open: Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain (clinicaltrials.gov) - Nov 12, 2014
P=N/A, N=3200, Recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Nov 2014 Not yet recruiting --> Recruiting
- ||||||| rivaroxaban / Generic mfg.
Trial completion: VENTURE-AF: A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy (clinicaltrials.gov) - Nov 7, 2014
P3, N=253, Completed, Sponsor: Janssen Scientific Affairs, LLC
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Clinical: Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 80 Years and Over (clinicaltrials.gov) - Nov 7, 2014
P=N/A, N=2193, Not yet recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
- |||| rivaroxaban / Generic mfg.
Trial primary completion date: PIONEER AF-PCI: A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention (clinicaltrials.gov) - Nov 6, 2014
P3, N=2169, Recruiting, Sponsor: Janssen Scientific Affairs, LLC
Active, not recruiting --> Completed Trial primary completion date: Mar 2016 --> Aug 2016
- ||| Enrollment closed, Enrollment change: Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring (clinicaltrials.gov) - Nov 6, 2014
P4, N=59, Active, not recruiting, Sponsor: Northwestern University
Trial primary completion date: Mar 2016 --> Aug 2016 Recruiting --> Active, not recruiting | N=75 --> 59
- rivaroxaban / Generic mfg.
Clinical: RASS: Rivaroxaban Acute Stroke Safety Study (clinicaltrials.gov) - Oct 31, 2014
P=N/A, N=50, Recruiting, Sponsor: University of Alberta
- ||| rivaroxaban / Generic mfg.
Trial completion: BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies (clinicaltrials.gov) - Oct 30, 2014
P=N/A, N=647, Completed, Sponsor: Bayer
Recruiting --> Active, not recruiting | N=75 --> 59 Recruiting --> Completed
- || rivaroxaban / Generic mfg.
Enrollment closed, Enrollment change, Trial primary completion date, HEOR: SAFARI: Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication (clinicaltrials.gov) - Oct 28, 2014
P=N/A, N=376, Active, not recruiting, Sponsor: Bayer
Recruiting --> Completed Recruiting --> Active, not recruiting | N=550 --> 376 | Trial primary completion date: Sep 2014 --> Dec 2014
- rivaroxaban / Generic mfg.
Clinical: Naco_Nîmes: Plasma Modifications Associated With Rivaroxaban® Treatment for Stroke Prevention (clinicaltrials.gov) - Oct 24, 2014
P=N/A, N=10, Not yet recruiting, Sponsor: Centre Hospitalier Universitaire de Nīmes
- | rivaroxaban / Generic mfg., aspirin / Generic mfg.
New P2 trial: Comparative Study of Prophylactic Agent for Venous Thromboembolism After Total Knee Arthroplasty (clinicaltrials.gov) - Oct 22, 2014
P2, N=370, Recruiting, Sponsor: Hanyang University Seoul Hospital
- ||| rivaroxaban / Generic mfg.
Enrollment open: Patient and Physician Knowledge of Key Safety Messages (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=500, Recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting | N=550 --> 376 | Trial primary completion date: Sep 2014 --> Dec 2014 Not yet recruiting --> Recruiting
- ||| rivaroxaban / Generic mfg.
Clinical: Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain (clinicaltrials.gov) - Oct 15, 2014
P=N/A, N=3200, Not yet recruiting, Sponsor: Bayer
- rivaroxaban / Generic mfg., aspirin / Generic mfg., clopidogrel / Generic mfg.
New P2 trial: RIVAL-PAD: Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb Ischemia (clinicaltrials.gov) - Oct 11, 2014
P2, N=40, Not yet recruiting, Sponsor: Ottawa Hospital Research Institute
- ||||| rivaroxaban / Generic mfg.
Enrollment closed, Enrollment change: VENTURE-AF: A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy (clinicaltrials.gov) - Oct 10, 2014
P3, N=253, Active, not recruiting, Sponsor: Janssen Scientific Affairs, LLC
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=200 --> 253
- rivaroxaban / Generic mfg.
Enrollment closed: RivaMoS2: Rivaroxaban Laboratory Monitoring in Switzerland 2: Therapeutic Dose (RivaMoS 2) (clinicaltrials.gov) - Oct 10, 2014
P=N/A, N=20, Active, not recruiting, Sponsor: Prof. Dr. Dr. med. Walter A. Wuillemin, MD, PhD
Recruiting --> Active, not recruiting | N=200 --> 253 Recruiting --> Active, not recruiting
- | rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg.
Biomarker, Trial completion, Trial primary completion date: Pharmacogenomic Study on PKD/PKC of Dabigatran Etexilate and Rivaroxaban (clinicaltrials.gov) - Oct 10, 2014
P2/3, N=64, Completed, Sponsor: Assistance Publique - H
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Oct 2014 --> Jun 2014
- || rivaroxaban / Generic mfg.
Trial primary completion date: XANTUS-EL: Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region (clinicaltrials.gov) - Sep 30, 2014
P=N/A, N=2500, Recruiting, Sponsor: Bayer
Active, not recruiting --> Completed | Trial primary completion date: Oct 2014 --> Jun 2014 Trial primary completion date: Sep 2015 --> Dec 2015
- ||| rivaroxaban / Generic mfg.
Trial completion, Surgery, Compliance: Russian Non-Interventional Study on Compliance of Venous Thromboembolism (VTE) (clinicaltrials.gov) - Sep 29, 2014
P=N/A, N=2345, Completed, Sponsor: Bayer
Trial primary completion date: Sep 2015 --> Dec 2015 Active, not recruiting --> Completed
- ||| rivaroxaban / Generic mfg.
Clinical: FIRST: Follow-up in Rivaroxaban Patients in Setting of Thromboembolism (clinicaltrials.gov) - Sep 28, 2014
P=N/A, N=1500, Not yet recruiting, Sponsor: King's College Hospital NHS Trust
- ||| rivaroxaban / Generic mfg.
Enrollment change: Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification (clinicaltrials.gov) - Sep 28, 2014
P4, N=253, Recruiting, Sponsor: RWTH Aachen University
Active, not recruiting --> Completed N=348 --> 253
- |||||||||| rivaroxaban / Generic mfg.
New P3 trial: EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis (clinicaltrials.gov) - Sep 9, 2014
P3, N=160, Not yet recruiting, Sponsor: Bayer
- || rivaroxaban / Generic mfg.
Enrollment change: Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism (clinicaltrials.gov) - Aug 29, 2014
P=N/A, N=100, Recruiting, Sponsor: Bayer
N=348 --> 253 N=150 --> 100
- rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
Surgery: Perioperative Anticoagulant Use for Surgery Evaluation Study (clinicaltrials.gov) - Aug 29, 2014
P=N/A, N=3291, Recruiting, Sponsor: McMaster University
- || rivaroxaban / Generic mfg.
Trial primary completion date: Xarelto Regulatory Post-Marketing Surveillance (clinicaltrials.gov) - Aug 27, 2014
P=N/A, N=4000, Recruiting, Sponsor: Bayer
N=150 --> 100 Trial primary completion date: Jul 2015 --> Feb 2015
- |||| rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
Trial primary completion date, Surgery: BRUISECONTROL2: Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events (clinicaltrials.gov) - Aug 21, 2014
P3, N=846, Recruiting, Sponsor: University of Ottawa Heart Institute
Trial primary completion date: Jul 2015 --> Feb 2015 Trial primary completion date: Oct 2014 --> Jun 2015
- |||||||||| AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
New P3 trial: A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban (clinicaltrials.gov) - Aug 21, 2014
P3, N=79, Recruiting, Sponsor: Portola Pharmaceuticals
- rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg.
Trial completion, Preclinical, Trial primary completion date: Effect of New Oral Anticoagulants Dabigatran and Rivaroxaban on Point of Care Coagulation Testing - an Ex-Vivo Study (clinicaltrials.gov) - Aug 15, 2014
P=N/A, N=34, Completed, Sponsor: Johann Wolfgang Goethe University Hospitals
Trial primary completion date: Oct 2014 --> Jun 2015 Recruiting --> Completed | Trial primary completion date: Mar 2013 --> Mar 2014
- rivaroxaban / Generic mfg.
Trial completion: A Prospective Pharmacodynamic Study of Rivaroxaban (clinicaltrials.gov) - Aug 4, 2014
P=N/A, N=65, Completed, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Completed | Trial primary completion date: Mar 2013 --> Mar 2014 Active, not recruiting --> Completed
- || rivaroxaban / Generic mfg.
Trial primary completion date: NEURO-XAR: Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients (clinicaltrials.gov) - Jul 28, 2014
P=N/A, N=214, Recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Trial primary completion date: Oct 2014 --> Jan 2015
- || rivaroxaban / Generic mfg.
Trial initiation date: XALIA: Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy (clinicaltrials.gov) - Jul 24, 2014
P=N/A, N=5169, Active, not recruiting, Sponsor: Bayer
Trial primary completion date: Oct 2014 --> Jan 2015 Initiation date: Jun 2012 --> Feb 2012
- |||| rivaroxaban / Generic mfg.
Trial primary completion date: PIONEER AF-PCI: A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention (clinicaltrials.gov) - Jul 1, 2014
P3, N=2169, Recruiting, Sponsor: Janssen Scientific Affairs, LLC
Initiation date: Jun 2012 --> Feb 2012 Trial primary completion date: Dec 2015 --> Mar 2016
- || rivaroxaban / Generic mfg.
Enrollment change: Patient and Physician Knowledge of Key Safety Messages (clinicaltrials.gov) - Jul 1, 2014
P=N/A, N=500, Not yet recruiting, Sponsor: Bayer
Trial primary completion date: Dec 2015 --> Mar 2016 N=4000 --> 500
- |||||| rivaroxaban / Generic mfg.
Enrollment open, Review, Journal: MARINER: A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients (clinicaltrials.gov) - Jun 24, 2014
P3, N=8000, Recruiting, Sponsor: Janssen Research & Development, LLC
N=4000 --> 500 Not yet recruiting --> Recruiting
- |||| rivaroxaban / Generic mfg.
Trial primary completion date: VENTURE-AF: A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy (clinicaltrials.gov) - Jun 22, 2014
P3, N=200, Recruiting, Sponsor: Janssen Scientific Affairs, LLC
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2014 --> Dec 2014
- | rivaroxaban / Generic mfg., aspirin / Generic mfg.
New P4 trial: OCEAN: Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial (clinicaltrials.gov) - Jun 22, 2014
P4, N=1452, Not yet recruiting, Sponsor: University of Ottawa Heart Institute
- || rivaroxaban / Generic mfg., aspirin / Generic mfg.
New P3 trial: MicroVasc-DIVA: Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Subclinical Inflammation and High Cardiovascular Risk (clinicaltrials.gov) - Jun 18, 2014
P3, N=188, Not yet recruiting, Sponsor: GWT-TUD GmbH
- rivaroxaban / Generic mfg.
Trial initiation date, Surgery: XYRIS: Study to Observe Safety of Xarelto in VTE Prophlylaxis After Elective TKR (Total Knee Replacement) or THR (Total Hip Replacement) (clinicaltrials.gov) - Jun 17, 2014
P=N/A, N=500, Suspended, Sponsor: Bayer
Trial primary completion date: Sep 2014 --> Dec 2014 Initiation date: May 2013 --> Sep 2013
- | Xarelto (rivaroxaban) / J&J, warfarin / Generic mfg.
New P4 trial: VICTORIA: Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation (clinicaltrials.gov) - Jun 13, 2014
P4, N=150, Recruiting, Sponsor: University Hospital, Angers
- | rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg.
Biomarker, Enrollment closed: Pharmacogenomic Study on PKD/PKC of Dabigatran Etexilate and Rivaroxaban (clinicaltrials.gov) - Jun 12, 2014
P2/3, N=60, Active, not recruiting, Sponsor: Assistance Publique - H
Initiation date: May 2013 --> Sep 2013 Recruiting --> Active, not recruiting
- || rivaroxaban / Generic mfg., warfarin / Generic mfg.
New P3 trial: TRAPS: Rivaroxaban in Thrombotic Antiphospholipid Syndrome (clinicaltrials.gov) - Jun 3, 2014
P3, N=536, Not yet recruiting, Sponsor: University of Padova
- rivaroxaban / Generic mfg.
Clinical: Evaluation of Effectiveness and Safety of Xa Inhibitor for the Prevention of Stroke And Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-valvular Atrial Fibrillation (clinicaltrials.gov) - May 22, 2014
P=N/A, N=7000, Recruiting, Sponsor: Tohoku University
- || rivaroxaban / Generic mfg.
Trial primary completion date: BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies (clinicaltrials.gov) - May 18, 2014
P=N/A, N=600, Recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2014 --> May 2014
- | rivaroxaban / Generic mfg.
Trial completion date: BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies (clinicaltrials.gov) - May 18, 2014
P=N/A, N=600, Recruiting, Sponsor: Bayer
Trial primary completion date: Apr 2014 --> May 2014 Trial completion date: Apr 2014 --> May 2014
- rivaroxaban / Generic mfg., warfarin / Generic mfg.
Trial initiation date: Rivaroxaban Estimation With Warfarin in Atrial Fibrillation Patients With Coronary Stent Implantation Study (REWRAPS) (clinicaltrials.gov) - May 18, 2014
P4, N=1600, Recruiting, Sponsor: Fujita Health University
Trial completion date: Apr 2014 --> May 2014 Initiation date: Jan 2014 --> May 2014
- rivaroxaban / Generic mfg., warfarin / Generic mfg.
Enrollment open: Rivaroxaban Estimation With Warfarin in Atrial Fibrillation Patients With Coronary Stent Implantation Study (REWRAPS) (clinicaltrials.gov) - May 18, 2014
P4, N=1600, Recruiting, Sponsor: Fujita Health University
Initiation date: Jan 2014 --> May 2014 Not yet recruiting --> Recruiting
- |||| rivaroxaban / Generic mfg., warfarin / Generic mfg.
Enrollment open: TripleAXEL: Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation (clinicaltrials.gov) - May 7, 2014
P2, N=196, Recruiting, Sponsor: Asan Medical Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | rivaroxaban / Generic mfg.
Trial completion date, HEOR: SAFARI: Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication (clinicaltrials.gov) - May 1, 2014
P=N/A, N=550, Recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting Trial completion date: Jun 2015 --> Mar 2015
- rivaroxaban / Generic mfg.
New P2 trial: CATHAR: Comparison of Antithrombotic Treatments After Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve. (clinicaltrials.gov) - Apr 23, 2014
P2, N=30, Recruiting, Sponsor: University Hospital Inselspital, Berne